# RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

> **NCT07416474** · PHASE3 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 574 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** RC148 plus Carboplatin and Paclitaxel
- **DRUG:** Tislelizumab plus Carboplatin and Paclitaxel

## Key facts

- **NCT ID:** NCT07416474
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-03
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-11-30
- **Target enrollment:** 574 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07416474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07416474, "RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07416474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*